BioCentury
ARTICLE | Clinical News

Angiochem preclinical data

December 15, 2014 8:00 AM UTC

In mice bearing intracranial HER2-positive tumors, twice-weekly 15 mg/kg IV ANG4043 significantly improved median overall survival (OS) vs. vehicle-treated controls (80 vs. 45 days, p=0.0003). Data we...